• Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company.
• The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024.
• The Board of Directors also declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible.
PRINCETON, N.J. / Sep 10, 2024 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024.
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on December 2, 2024, to stockholders of record at the close of business on November 5, 2024.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.
| Last Trade: | US$49.34 |
| Daily Change: | -0.40 -0.80 |
| Daily Volume: | 2,211,472 |
| Market Cap: | US$100.160B |
September 18, 2024 September 09, 2024 August 26, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
